指南与共识术前评估与围术期医学

欧洲恶性高热组2025年恶性高热易感性检查指南

European Malignant Hyperthermia Group 2025 guidelines for the investigation of malignant hyperthermia susceptibility.
指南 / 共识 · Br J Anaesth · 2026-01-01

该指南由欧洲恶性高热组制定,在DNA检测方法取得重大进展后对上一版指南进行了全面修订。除保留体外氟烷/咖啡因收缩试验的易感性分类外,新增了「恶性高热基因型」诊断命名,并更新了患者转诊标准和诊断结果的临床解读,首次给出临床恶性高热事件的共识定义。

要点

  • 新增「恶性高热基因型」诊断命名,修订诊断路径并调整基因变异分类体系。
  • 体外氟烷/咖啡因收缩试验方案有小幅修改,患者转诊标准同步更新。
  • 首次提供临床恶性高热事件的共识定义。

核心结论

  • 指南全面修订恶性高热易感性检查方法,引入恶性高热基因型诊断命名并更新诊断路径。

研究设计与样本

  • 欧洲恶性高热组发布的指南,在上一版更新10年后依据DNA检测方法的重要进展进行全面修订。

主要发现

  • 在体外氟烷/咖啡因收缩试验的易感性分类之外,新增恶性高热基因型这一诊断命名。
  • 修订后的诊断路径纳入了调整后的欧洲恶性高热组基因变异分类系统。
  • 对体外氟烷/咖啡因收缩试验方案做了小幅修改。
  • 更新了患者转诊标准和诊断结果的临床解读。
  • 首次给出临床恶性高热事件的共识定义。

关键数值与推荐

  • 恶性高热易感性分类沿用体外氟烷/咖啡因收缩试验。
  • 新增恶性高热基因型作为诊断命名,并配套调整后的基因变异分类系统。

临床怎么用

  • 麻醉科医生应按更新后的转诊标准筛选需行恶性高热易感性检查的患者。
  • 诊断解读需区分体外收缩试验分类与新增的恶性高热基因型。
  • 临床可按指南首次给出的共识定义判定恶性高热事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since malignant hyperthermia (MH) was first described in 1960, the number of cases of this potentially life-threatening reaction to anaesthesia with fatal or serious outcomes has been markedly reduced thanks to continuous advances in knowledge about triggering, clinical course, and treatment. Another essential and evolving pillar of patient safety remains diagnostics, which serve to confirm or rule out suspected cases of MH and to identify other individuals at risk of MH for prevention. For more than 40 yr, the British Journal of Anaesthesia has published the updated consensus diagnostic protocols of the European Malignant Hyperthermia Group at regular intervals. The presented diagnostic guidelines have been comprehensively revised 10 yr after the last update after substantial advances in DNA-based testing methods. In addition to the previous classification of MH susceptibility by the in vitro halothane/caffeine contracture test, a new diagnostic designation, the MH genotype, has been introduced. The latter is reflected in the revised diagnostic pathways, which also include the adapted European Malignant Hyperthermia Group curation system for the classification of genetic variants with regard to their relevance to MH. In addition to minor changes in the in vitro halothane/caffeine contracture test protocol, the guidelines address updated patient referral criteria and clinical interpretation of diagnostic results. And for the first time, the guidelines provide a consensus definition of a clinical MH event.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Rüffert H, Gillies R, Hopkins PM, et al. European Malignant Hyperthermia Group 2025 guidelines for the investigation of malignant hyperthermia susceptibility. Br J Anaesth. 2026. PMID: 41478797. doi:10.1016/j.bja.2025.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。